Abstract
A neoantigen derived from mutant IDH1 can promote antitumor CD4(+) T-cell and antibody responses.
©2014 American Association for Cancer Research.
MeSH terms
-
Animals
-
Cancer Vaccines / immunology*
-
Cancer Vaccines / therapeutic use*
-
Female
-
Glioma / immunology*
-
Glioma / therapy*
-
Humans
-
Isocitrate Dehydrogenase / genetics*
-
Isocitrate Dehydrogenase / immunology*
-
Male
-
Mutant Proteins / immunology*
Substances
-
Cancer Vaccines
-
Mutant Proteins
-
Isocitrate Dehydrogenase